Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer...

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• CDK4/cyclin D kinase is a key target for anticancer therapeutics, especially in KRAS-mutant lung cancer with limited treatment options.
• Existing ATP-competitive CDK4 inhibitors show insufficient specificity and efficacy.
• KRAS mutations are prevalent in lung cancer, correlating with CDK4/cyclin D levels.

Purpose of the Study:

• To develop a novel therapeutic agent targeting the CDK4/cyclin D interaction.
• To evaluate the efficacy of a stapled peptide inhibitor in preclinical lung cancer models.

Main Methods:

• Design and characterization of a stapled peptide targeting the CDK4/cyclin D interface.
• Assessment of physico-chemical properties and binding affinity to cyclin D1.
• In vitro evaluation of kinase inhibition and cell proliferation in lung cancer cells.
• In vivo studies involving intrapulmonary administration in mice with orthotopic lung tumors.

Main Results:

• A positive correlation was confirmed between CDK4/cyclin D levels and KRAS mutations in lung cancer patients.
• The stapled peptide demonstrated rapid and efficient cellular uptake.
• The peptide effectively inhibited CDK4 kinase activity and lung cancer cell proliferation.
• Intrapulmonary administration in mice led to tumor retention and complete tumor growth inhibition when combined with Abemaciclib.

Conclusions:

• The developed stapled peptide offers a promising therapeutic strategy for lung cancer, particularly for KRAS-mutant cases.
• Targeting the CDK4/cyclin D interface with this peptide overcomes limitations of traditional inhibitors.
• Preclinical data support the potential of this stapled peptide as a novel lung cancer therapy.